FIELD: pharmaceutics.
SUBSTANCE: invention relates to the field of pharmaceutics, namely to an ophthalmic composition for use on the edge of the eyelid for the treatment of dysfunction of meibomian glands. The composition contains from 0.05% by wt. to 2.5% by wt. of selenium disulfide and an anhydrous semi-solid ophthalmic base, wherein the composition does not essentially contain surfactants and dispersing agents. The anhydrous semi-solid ophthalmic base is mineral oil or Vaseline base. Selenium disulfide particles have an average diameter of less than 50 mcm.
EFFECT: providing an ophthalmic composition containing selenium disulfide and anhydrous semi-solid ophthalmic base for use on the edge of the eyelid for the treatment of dysfunction of meibomian glands.
11 cl, 5 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF TREATING MEIBOMIAN DYSFUNCTION | 2015 |
|
RU2730464C2 |
| METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISEASES | 2016 |
|
RU2691412C2 |
| THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | 2014 |
|
RU2709542C2 |
| OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR SURFACE DAMAGE AND DRY EYE SYMPTOMS | 2019 |
|
RU2806212C2 |
| OPHTHALMIC COMPOSITION | 2012 |
|
RU2625301C2 |
| EYE DISEASE TREATMENT | 2020 |
|
RU2816363C2 |
| CYCLOSPORINE SUSPENSIONS A OF FORM 2 | 2012 |
|
RU2641963C2 |
| NEW USE OF NICOTINAMIDE MONONUCLETIDE (NMN) AND NICOTINAMIDE RIBOSIDE (NR) | 2020 |
|
RU2822512C2 |
| AQUEOUS OPHTHALMIC SOLUTION AND METHOD OF TREATING DRY EYE SYNDROME | 2015 |
|
RU2688935C2 |
| COMPOSITION OF PROLONGED ACTION OF CYCLOSPORIN OF FORM 2 | 2012 |
|
RU2639393C2 |
